We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why You Should Buy CME Group (CME) Stock Right Now
Read MoreHide Full Article
Shares of CME Group Inc. (CME - Free Report) jumped 33.8% in a year’s time, outperforming the 23.5% growth for the Zacks categorized Securities Exchanges industry. We see potential upside for the stock in the near term, given the company’s strength in several areas.
Based in Chicago, IL, CME Group is a major and most diverse derivatives marketplace. It offers a broad range of products, covering major asset classes, based on interest rates, equity indexes, foreign exchange, energy, agricultural commodities and metals. Trades can be executed through the company’s electronic trading platforms or open outcry.
Why is the Stock an Attractive Pick?
Improving Volumes to Support Revenue: In recent years, CME Group has managed to register decent growth in its clearing and transaction fees, which constitutes over 80% of the company’s total revenues. The increase in the fees has been primarily driven by rising volumes. Notably, amid increased volatility driven by the U.S. presidential election and the December Fed rate hike, CME Group’s average daily volume (ADV) for fourth-quarter 2016 surged 24% year over year to 16.3-million contracts, with growth across five of the six product lines.
Earnings per Share Growth: CME Group has witnessed more than 12% rise in earnings per share in the last three years. It remains well positioned for growth on the back of its strong market position with diverse derivative product lines. Efforts to expand and cross sell its core exchange-traded business through strategic alliances & acquisitions, new product initiatives and global reach should further support its earnings momentum. Notably, the company has long-term expected earnings per share (EPS) growth rate of 9.9%.
Steady Capital Deployment Activities: Driven by financial strength, CME Group remains committed to boost shareholder’s value. Last December, the company announced annual variable dividend of $3.25 per share, totaling about $1.1 billion. CME Group pays five dividends per year, with the fifth being variable which is based on excess cash flow in the year. Since it commenced the annual variable dividend structure in 2012, CME Group’s return to shareholders amounted to more than $7.5 billion in quarterly and variable dividends.
Upward Estimates Revisions: CME Group has been witnessing upward estimate revisions, ahead of its fourth-quarter 2016 results. Over the past 30 days, the Zacks Consensus Estimate for the quarter advanced 9.1% to $1.08. Also, for 2016, it inched up 1.6% to $4.45. The positive earnings estimate revisions indicate analysts’ confidence and substantiate the Zacks Rank #2 (Buy) for the stock. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Other Stocks to Consider
CBOE Holdings, Inc. (CBOE - Free Report) : Over the last 30 days, the Zacks Consensus Estimate for fourth-quarter 2016 increased 3.5% to 59 cents per share and climbed nearly 1% to $2.938 for 2016. The company carries a Zacks Rank #2.
The PNC Financial Services Group, Inc. (PNC - Free Report) : The Zacks Consensus Estimate for fourth-quarter 2016 climbed 1.6% to $1.86, over the past 30 days. In addition, it moved up slightly to $7.18 for 2016. The company also carries a Zacks Rank #2.
Cullen/Frost Bankers, Inc. (CFR - Free Report) : Over the past 30 days, the Zacks Consensus Estimate for fourth-quarter 2016 advanced 1% to $1.24 and slightly moved up to $4.64 for 2016. The company has a Zacks Rank #2 (Buy).
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2017?
Who wouldn't? As of early December, the 2016 Top 10 produced 5 double-digit winners including oil and natural gas giant Pioneer Natural Resources which racked up a stellar +50% gain. The new list is painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. Be among the very first to see it>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why You Should Buy CME Group (CME) Stock Right Now
Shares of CME Group Inc. (CME - Free Report) jumped 33.8% in a year’s time, outperforming the 23.5% growth for the Zacks categorized Securities Exchanges industry. We see potential upside for the stock in the near term, given the company’s strength in several areas.
Based in Chicago, IL, CME Group is a major and most diverse derivatives marketplace. It offers a broad range of products, covering major asset classes, based on interest rates, equity indexes, foreign exchange, energy, agricultural commodities and metals. Trades can be executed through the company’s electronic trading platforms or open outcry.
Why is the Stock an Attractive Pick?
Improving Volumes to Support Revenue: In recent years, CME Group has managed to register decent growth in its clearing and transaction fees, which constitutes over 80% of the company’s total revenues. The increase in the fees has been primarily driven by rising volumes. Notably, amid increased volatility driven by the U.S. presidential election and the December Fed rate hike, CME Group’s average daily volume (ADV) for fourth-quarter 2016 surged 24% year over year to 16.3-million contracts, with growth across five of the six product lines.
Earnings per Share Growth: CME Group has witnessed more than 12% rise in earnings per share in the last three years. It remains well positioned for growth on the back of its strong market position with diverse derivative product lines. Efforts to expand and cross sell its core exchange-traded business through strategic alliances & acquisitions, new product initiatives and global reach should further support its earnings momentum. Notably, the company has long-term expected earnings per share (EPS) growth rate of 9.9%.
Steady Capital Deployment Activities: Driven by financial strength, CME Group remains committed to boost shareholder’s value. Last December, the company announced annual variable dividend of $3.25 per share, totaling about $1.1 billion. CME Group pays five dividends per year, with the fifth being variable which is based on excess cash flow in the year. Since it commenced the annual variable dividend structure in 2012, CME Group’s return to shareholders amounted to more than $7.5 billion in quarterly and variable dividends.
Upward Estimates Revisions: CME Group has been witnessing upward estimate revisions, ahead of its fourth-quarter 2016 results. Over the past 30 days, the Zacks Consensus Estimate for the quarter advanced 9.1% to $1.08. Also, for 2016, it inched up 1.6% to $4.45. The positive earnings estimate revisions indicate analysts’ confidence and substantiate the Zacks Rank #2 (Buy) for the stock. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Other Stocks to Consider
CBOE Holdings, Inc. (CBOE - Free Report) : Over the last 30 days, the Zacks Consensus Estimate for fourth-quarter 2016 increased 3.5% to 59 cents per share and climbed nearly 1% to $2.938 for 2016. The company carries a Zacks Rank #2.
The PNC Financial Services Group, Inc. (PNC - Free Report) : The Zacks Consensus Estimate for fourth-quarter 2016 climbed 1.6% to $1.86, over the past 30 days. In addition, it moved up slightly to $7.18 for 2016. The company also carries a Zacks Rank #2.
Cullen/Frost Bankers, Inc. (CFR - Free Report) : Over the past 30 days, the Zacks Consensus Estimate for fourth-quarter 2016 advanced 1% to $1.24 and slightly moved up to $4.64 for 2016. The company has a Zacks Rank #2 (Buy).
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2017?
Who wouldn't? As of early December, the 2016 Top 10 produced 5 double-digit winners including oil and natural gas giant Pioneer Natural Resources which racked up a stellar +50% gain. The new list is painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. Be among the very first to see it>>